Drug intelligence / Profile preview

VitaKine

Development stage: Preclinical
Lead developer: BioParadox
Modality: Cell Therapies
Administration: Intramyocardial

Overview

**VitaKine** is a platelet cell therapy developed by BioParadox, Inc., utilizing Platelet-Cell Therapy (PCT) technology for regenerative treatment of cardiovascular disease, particularly improving cardiac function. It involves point-of-care biologic treatments derived from platelets to promote tissue repair and regeneration in damaged heart tissue. The therapy is part of BioParadox's pipeline, which also includes RevaTen, aimed at addressing unmet needs in heart failure and related conditions through autologous cell-based approaches.

Brand names: VitaKine

Beyond the preview

Go deeper on VitaKine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VitaKine.

Explore the full profile